Abstract #2801
DCE-MRI
at 3T in Patients with Advanced Prostate Cancer Undergoing Androgen
Deprivation Therapy
Tristan Barrett1, Andrew Gill1,2,
Masako Kataoka1, Vincent J. Gnanapragasam3, Andrew
Priest1,2, Ilse Joubert1, Mary McLean2,4,
Martin J. Graves1, David J. Lomas1, John R. Griffiths2,
David Neal3,5, Evis Sala1
1Radiology, Addenbrooke's Hospital,
Cambridge, United Kingdom; 2Medical Physics, Addenbrooke's
Hospital, Cambridge, United Kingdom; 3Urology, Addenbrooke's
Hospital, Cambridge, United Kingdom; 4 Cambridge Research
Institute, Cancer Research UK,, Cambridge, United Kingdom; 5Cambridge
Research Institute, Cancer Research UK, Cambridge, United Kingdom
Prostate
cancer is the commonest malignancy in UK men. Androgen deprivation
therapy (ADT) remains an important treatment. However, 51% eventually develop
resistance, making it necessary to identify quantitative markers that
demonstrate ADT response. We used dynamic-contrast-enhancement (DCE)-MRI to
measure permeability parameters before and 3 months after ADT in 12 patients
with biopsy-proven prostate cancer. There was a significant reduction in all
parameters measured (Ktrans, kep, Ve, IAUGC-90), whereas normal tissue
showed no significant change. These results suggest that DCE-MRI has potential
to monitor ADT response and select to patients with AD resistance at early
time-points, allowing consideration of other treatments.
